ADCs combine antibodies with drug payloads for targeted therapy, but complex manufacturing requires monitoring CQAs across multiple entities.
NAMkind™ models have now been tested against a wide set of marketed ADC molecules, showing close correlation with clinical results in terms of the toxic impact in the liver and side effect profile in ...
Merck’s decision to establish oncology as a standalone business unit is easy to describe and tempting to oversimplify. At ...
As quantum computers continue to advance, many of today's encryption systems face the risk of becoming obsolete. A powerful ...
As drug potency increases, OEB 6 containment is becoming increasingly crucial for safe HPAPI manufacturing, driven by oncology growth, and complex payloads.
A laser-written glass chip shows how fragile quantum signals can be decoded with high stability and low loss, offering a new ...
Early-phase oncology trials carry substantial scientific and commercial risk in cancer drug development. Getting them right ...
Q4 2025 Earnings Call February 9, 2026 8:30 AM ESTCompany ParticipantsCaspar Tudor - Head of Investor RelationsUdit Batra ...
Q4 2025 Earnings Call February 10, 2026 4:30 PM ESTCompany ParticipantsJacquie Ross - Senior Vice President of Treasury ...
First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY ...
Evogene Ltd. , a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Systasy Bioscience GmbH, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results